Grail Inc

NASDAQ:GRALUnited States

Oct 23, 2024

Show headlines and story abstract

• GRAIL Presents Initial Results From REFLECTION Real-World Evidence Study of Galleri(R) Multi-Cancer Early Detection (MCED) Test at the Early Detection of Cancer Conference, from 6:00PM ET on Wednesday Oct 23, 2024 by PR Newswire

  6:00PM ET on Wednesday Oct 23, 2024 by PR Newswire
  Companies Mentioned: GRAL

  Study Participants from Veteran AffairsSitesInclude a Diverse Population With Toxic Exposure

  GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced earlyresults from the REFLECTION study, which aims to understand the real-world experience of the Galleri(R)multi-cancer early detection (MCED) test in routine clinical settings. The Galleri test is recommended for adults with an elevated risk for cancer, such as those age 50 or older. In this study, adiverse population of veterans fromU.S. Department of Veterans Affairs (VA) sites with toxic exposure but with no symptoms suggestive of cancer were included in study enrollment. Initial results showed that among study participants, the veteran cohort had a cancer signal detection rate consistent with other populations that have received the MCED test. The findings were presented during a presentation at the 2024 Early Detection of Cancer Conference (EDCC).